Actinium Pharmaceuticals, Inc. is making progress with Iomab-ACT, an experimental treatment designed to improve stem cell transplants for sickle cell disease (SCD). The therapy uses targeted radiation to clear diseased bone marrow, making room for healthy donor stem cells — a potential step toward a cure.

How It Works:

✅Iomab-ACT delivers radiation directly to bone marrow, sparing healthy tissues

✅Helps prepare the body for donor stem cells by removing defective blood cells

✅Could offer a safer alternative to harsh chemotherapy-based conditioning

The research team at Columbia University is currently testing Iomab-ACT in clinical trials, with results expected in 2025. If the treatment proves effective, it could open up stem cell transplants to more sickle cell patients who currently can’t tolerate the harsh side effects of standard conditioning treatments.

At OxyDial, we see this as an important development for the SCD community. Many patients face barriers to transplants due to risks from traditional conditioning. Innovations like Iomab-ACT could make this lifesaving treatment more accessible.

Learn more: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-provides-business-update-after-presentation-at-trump-mar-a-lago-club-announcing-novel-non-psma-prostate-cancer-radiotherapy-atnm-400-and-outlining-revitalized-clinical-pipeline-with-2025-corporate-objectiv-302413074.html

#SickleCellDisease #SCD #StemCellTransplant #GeneTherapy #Hematology #MedicalInnovation